Oncology M&A in 2025–2026: What the Deals Reveal About the Future of Cancer Drug Development

Overview and Market Context

The period from January 2025 through July 2026 has produced one of the most consequential consolidation waves in oncology pharmaceutical history. Cancer research and development partnerships generated 78 deals worth $46.9 billion in the first half of 2025 alone, with average upfront payments rising sharply to $195 million—nearly double the prior year's $103 million—reflecting a deliberate shift toward fewer but significantly richer individual transactions 10. Full-year oncology M&A in 2025 delivered 19 deals totaling $22 billion including contingents, already surpassing 2024's full-year value of $20.4 billion, and momentum accelerated further into 2026 11. Aggregate oncology-focused deal values across this period have been estimated at $12–15 billion for acquisitions alone, with licensing and collaboration structures inflating total committed capital considerably higher 13.

For medical professionals, these transactions are not merely financial events. They constitute a collective industry wager on which therapeutic mechanisms, modalities, and patient populations are most likely to define oncology standards of care over the next decade. Reading this landscape carefully can anticipate what therapies will enter clinical practice, which biomarker strategies will become routine, and where clinical trials are likely to focus.

The Strategic Logic: What Acquirers Are Actually Buying

Across the transactions of this period, four distinct purchasing rationales emerge. First, acquirers are buying validated biology with visible efficacy signals. GSK's $1.15 billion acquisition of IDRx and its IDRX-42, a selective KIT tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumours (GIST, 胃肠道间质瘤), exemplifies this precisely: the asset demonstrated an objective response rate (ORR) of 29% across all evaluable patients (n=87) and 53% among patients with one prior line of therapy (n=15) in the StrateGIST 1 Phase I/Ib trial, with treatment-related adverse events predominantly low-grade 113. Critically, IDRX-42 inhibits the full spectrum of primary (exon 9, 11) and secondary (exon 13, 17) KIT mutations that drive resistance to existing agents—a mechanistically coherent, resistance-informed rationale that translated directly into deal value 1.

Second, acquirers are buying late-stage de-risked assets approaching commercial milestones. Gilead Sciences' $7.8 billion acquisition of Arcellx centres on anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR-T-cell therapy for relapsed/refractory multiple myeloma whose Biologics License Application (BLA) was accepted by the FDA with an anticipated PDUFA date of December 23, 2026, supported by pivotal Phase 2 iMMagine1 data showing deep and durable responses 7. GSK's $10.6 billion acquisition of Nuvalent—the company's largest deal in more than a decade—targets neladalkib, an ALK inhibitor, and zidesamtinib, a ROS1 inhibitor—both addressing genomically defined lung cancers with U.S. regulatory decisions expected in September and November 2026 and projected combined peak annual sales of $3–4 billion 14. Premium valuations for near-commercial assets reflect pharma's willingness to compress development timelines at a price.

Third, acquirers are buying combination backbones and platform optionality. The recurring theme of PD-1/PD-L1 plus VEGF/VEGF-A targeting through bispecific antibodies (双特异性抗体)—seen in BioNTech's acquisition of Biotheus for BNT327 ($800 million), subsequently licensed to Bristol Myers Squibb for $1.5 billion upfront plus $2 billion in fixed payments and up to $7.6 billion in milestones 10; Pfizer's $1.25 billion upfront licensing of SSGJ-707 from 3SBio 5; and AbbVie's $650 million upfront licensing of RC148 from RemeGen 4—signals industry consensus that dual checkpoint plus anti-angiogenic biology represents the next immuno-oncology backbone, designed for use in combination with antibody-drug conjugates (ADCs, 抗体偶联药物) and other agents.

Fourth, acquirers are buying manufacturing innovation and manufacturing simplification. AstraZeneca's $1 billion acquisition of EsoBiotec and its ENaBL (Engineered NanoBody Lentiviral) in vivo cell therapy platform, followed by Eli Lilly's up-to-$7 billion acquisition of Kelonia Therapeutics and its iGPS® in vivo gene placement system, both target the fundamental logistical barriers of traditional ex vivo CAR-T therapy—leukapheresis, weeks of manufacturing, lymphodepleting chemotherapy, and specialized centres 39. Both platforms deliver genetic instructions to T cells directly in vivo via IV injection, with Kelonia's KLN-1010 presenting encouraging early data at the 2025 American Society of Hematology (ASH) Annual Meeting plenary 9.

Therapeutic Modality Trends

Antibody-Drug Conjugates represent the most competed domain. Merck's ongoing collaboration with Daiichi Sankyo ($5.5 billion upfront, up to $16.5 billion in milestones) for three ADC candidates—patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan—reflects access to what Merck characterized as "one of the strongest leaders in the ADC space" 16. Gilead's $5 billion acquisition of Tubulis GmbH introduces TUB-040, targeting NaPi2b in ovarian cancer and non-small cell lung cancer (NSCLC), and TUB-030 across solid tumors, with leadership describing competitive early-trial data 15. Most importantly, Novartis's acquisition of Myricx Bio for up to $1.5 billion signals a payload paradigm shift: Myricx targets N-myristoyltransferase (NMT), an enzyme critical to protein stability, providing an ADC payload that does not rely on topoisomerase-I or tubulin inhibition—potentially circumventing the resistance and toxicity profiles that constrain conventional ADC payloads 18. Roche's licensing of MediLink's YL201, a B7H3-targeting ADC using the TMALIN® tumor microenvironment-activatable linker platform, for $570 million upfront, and its two Phase III registrational trials in China alongside FDA Breakthrough Therapy Designation for small cell lung cancer (SCLC), further validate the ADC space 4.

Bispecific and Multi-Specific Antibodies have achieved deal-class status. Beyond the PD-1/VEGF cluster, BeOne Medicines' April 2026 option on HH160—a trispecific antibody simultaneously targeting PD-1, CTLA-4, and VEGF-A—valued at up to $1.9 billion, illustrates escalating complexity in multi-mechanism immune targeting 12. Astellas' licensing of Vir Biotechnology's VIR-5500, a masked CD3 T-cell engager targeting PSMA in prostate cancer, reflects growing confidence in T-cell engagers as precision oncology modalities 12.

Precision Small Molecules in Rare and Defined Tumors remain strongly attractive. Merck KGaA's $3.9 billion acquisition of SpringWorks Therapeutics brings two FDA-approved agents: OGSIVEO (nirogacestat, a gamma-secretase inhibitor for desmoid tumors) and GOMEKLI (mirdametinib, the first FDA-approved therapy for NF1-associated plexiform neurofibromas in patients aged 2 years and older, approved February 2025 following Phase 2b ReNeu data) 2. Sanofi's $9.5 billion acquisition of Blueprint Medicines, anchored by Ayvakit for GIST and systemic mastocytosis alongside late-stage elenestinib, reflects continued conviction in KIT pathway kinase inhibition in rare indications 10.

Radiopharmaceuticals are gaining institutional legitimacy. RayzeBio (a Bristol Myers Squibb subsidiary) licensed Philochem's OncoACP3 for $350 million upfront plus up to $1 billion in milestones, targeting ACP3 in prostate cancer diagnosis and therapy 10. While this Phase I asset carries significant development uncertainty, the upfront premium signals pharma's recognition that radioligand therapies represent a validated and scalable modality for solid tumors.

The China and Japan Factor

Chinese biotech innovation has achieved critical mass in global oncology M&A. The value of China-origin licensing deals in the greater China region rose nearly tenfold from 2021 to an unprecedented $137.7 billion in 2025 17. Pfizer's May 2026 agreement with Innovent Biologics covering 12 early-stage ADC and multi-specific antibody programs is valued at up to $10.5 billion 17. Bristol Myers Squibb's May 2026 collaboration with Hengrui Pharma across 13 programs in oncology, hematology, and immunology reached up to approximately $15.2 billion 12. These deals reflect a geographic arbitrage model: Chinese biotechs conduct early clinical work leveraging cost-efficient infrastructure and large patient populations, while Western pharma acquires global development and commercial rights.

Japan's Daiichi Sankyo remains central to ADC development through its collaboration with Merck and separate partnership with AstraZeneca, positioning Japanese ADC manufacturing and linker expertise as a critical global competitive asset 16.

Structured Comparison of Key Transactions

Implications for Future Oncology R&D and Clinical Practice

Several conclusions emerge from this M&A landscape with direct relevance for clinical professionals.

In vivo cell therapy may reshape CAR-T accessibility. Both AstraZeneca's ENaBL and Lilly's iGPS® platforms premise that manufacturing simplification—IV administration without apheresis or lymphodepletion—could be as clinically transformative as efficacy gains. If Kelonia's Phase 1 signals hold through late-stage development, oncologists could administer cell therapies in outpatient settings rather than specialized centres, fundamentally altering the patient pathway 93.

ADC payload diversification will demand updated safety monitoring. The Novartis–Myricx NMTi payload, the Gilead–Tubulis NaPi2b-targeting platform, and MediLink's TMALIN® microenvironment-activatable linker each introduce mechanisms with distinct toxicity profiles from established topoisomerase-I inhibitor payloads. Clinicians managing ADC-related adverse events will need to adapt to payload-specific toxicity patterns and drug-drug interaction profiles as these candidates advance 18154.

Bispecific antibody combinations with ADCs will define next-generation solid tumor regimens. The explicit rationale in the AbbVie–RC148 and BMS–BNT327 transactions is to deploy these agents in combination with ADCs, not as monotherapies. Future clinical trials will likely evaluate triple combinations—bispecific antibody plus ADC plus chemotherapy—requiring careful attention to cumulative toxicity, pharmacokinetics, and patient selection by biomarker 410.

Biomarker-driven and mutation-comprehensive trial designs will accelerate. From IDRX-42's multi-exon KIT mutation coverage in GIST to Nuvalent's ALK-mutation-specific agents to anito-cel's BCMA-directed targeting, the acquired assets all embody precision patient selection. Medical professionals should anticipate increasing requirements for companion diagnostics, expanded mutation panel testing, and adaptive trial designs that stratify patients by resistance mutation status from enrollment 1714.

Chinese and Japanese biotech expertise will continue to drive ADC and multi-specific antibody innovation. The $137.7 billion in China-region licensing value in 2025, the Pfizer–Innovent and BMS–Hengrui deals in 2026, and the ongoing Merck–Daiichi Sankyo collaboration collectively indicate that the global oncology innovation ecosystem has genuinely distributed—and that future standards of care in solid tumors will be shaped by scientific programs originating as much in Shanghai and Tokyo as in Boston or Basel 171216.

In aggregate, the 2025–2026 oncology M&A landscape reveals an industry betting on a future of rational polypharmacology: precision mechanisms layered to address resistance, simplified manufacturing to democratize access, and platform ownership to sustain long-term competitive advantage across multiple indications and combinations. For oncologists, hematologists, and clinical researchers, anticipating these trajectories is no longer optional—it is foundational to understanding where the next standards of care are being built.